Back to Results

China SXT Pharmaceuticals Inc (SXTC)

China SXT Pharmaceuticals Inc (NASDAQ-SXTC) is a Healthcare company whose common stock is listed on NASDAQ. The security context is common equity, so this overview refers to the company’s publicly traded shares rather than a fund, note, or other instrument. China SXT Pharmaceuticals Inc operates in the pharmaceuticals industry and is associated with traditional Chinese medicine products and related pharmaceutical activities in China. Its business profile is tied to the development, production, marketing, and sale of medicinal materials and prepared items used in that market. This summary is limited to the listed common stock and avoids broader claims about performance or operating scale.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-SXTC
$3.47
40.5% Upside
Undervalued
Not available
Not available
Weak
0.0%
0.1x
2.9x
3.264 M
-23.936 M
26.2%
99.7%
10.5
64.8%
Valuation • Fair Value

China SXT Pharmaceuticals Inc (NASDAQ-SXTC) Fair Value by Valuation Model

Review the available estimates for China SXT Pharmaceuticals Inc (NASDAQ-SXTC), including Comps Fair Value.

Primary Valuation Read

Fair Value

$3.47

Estimated upside of 40.5% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Comps Fair Value

$3.47

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for China SXT Pharmaceuticals Inc (NASDAQ-SXTC) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for China SXT Pharmaceuticals Inc (NASDAQ-SXTC)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

1.138 M

Current operating scale indicator.

Revenue Forecast

1.138 M

Forward revenue estimate.

EBITDA

-7.049 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review China SXT Pharmaceuticals Inc (NASDAQ-SXTC) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for China SXT Pharmaceuticals Inc (NASDAQ-SXTC)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-3.60

No elevated caution signal from this screen.

Altman Z-Score

10.5

Relatively strong balance-sheet zone.

FCF / Net Income

64.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for China SXT Pharmaceuticals Inc (NASDAQ-SXTC). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for China SXT Pharmaceuticals Inc (NASDAQ-SXTC)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for China SXT Pharmaceuticals Inc (NASDAQ-SXTC). No upcoming dividend amount or event date is currently available.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for China SXT Pharmaceuticals Inc (NASDAQ-SXTC) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for China SXT Pharmaceuticals Inc (NASDAQ-SXTC) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for China SXT Pharmaceuticals Inc (NASDAQ-SXTC) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for China SXT Pharmaceuticals Inc (NASDAQ-SXTC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for China SXT Pharmaceuticals Inc (NASDAQ-SXTC) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

China SXT Pharmaceuticals Inc (NASDAQ-SXTC) Stock FAQ

Data-supported answers about China SXT Pharmaceuticals Inc (NASDAQ-SXTC), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$3.47
Estimated upside 40.5%
Valuation Rating
Undervalued
Estimated upside of 40.5%
Financial Health
Weak
Current financial-health read

The current fair value estimate for China SXT Pharmaceuticals Inc (NASDAQ-SXTC) is $3.47. This implies an estimated upside of 40.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 40.5% versus the current market price.

The current financial health read for China SXT Pharmaceuticals Inc (NASDAQ-SXTC) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for China SXT Pharmaceuticals Inc (NASDAQ-SXTC).

The current market capitalization listed for China SXT Pharmaceuticals Inc is 3.264 M.

The current enterprise value listed for China SXT Pharmaceuticals Inc is -23.936 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for China SXT Pharmaceuticals Inc is NASDAQ-SXTC, and the stock is listed on NASDAQ.

China SXT Pharmaceuticals Inc (NASDAQ-SXTC) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for China SXT Pharmaceuticals Inc is 26.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for China SXT Pharmaceuticals Inc is 99.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B